PRAX Praxis Precision Medicines
- 39.875
- +1.815+4.77%
Praxis Precision Medicines News
Needham Initiates Coverage On Praxis Precision Medicine With Buy Rating, Announces Price Target of $145
Praxis Precision Medicine Analyst Ratings
Praxis Precision Medicine Analyst Ratings
Guggenheim Initiates Coverage On Praxis Precision Medicine With Buy Rating, Announces Price Target of $155
Praxis Precision Medicines Inc: Jefferies Raises Price Target from $128 to $141
Analysts' Top Healthcare Picks: Praxis Precision Medicines (PRAX), Corbus Pharmaceuticals (CRBP)
Praxis Precision Medicine Analyst Ratings
Buy Rating Backed by Robust Pipeline and Market Opportunity for Praxis Precision Medicines
Praxis Precision Medicine Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Bluebird Bio (BLUE) and Nuvalent (NUVL)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Theravance Biopharma (TBPH), Voyager Therapeutics (VYGR) and Praxis Precision Medicines (PRAX)
Praxis Precision Medicine (PRAX.US) was first covered by Baird, which gave it an superior market rating, with a target price of $117.00.
Praxis Precision Medicine Analyst Ratings
Baird Initiates Coverage On Praxis Precision Medicine With Outperform Rating, Announces Price Target of $117
Praxis Precision Medicine Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)
Wedbush Trims Price Target on Praxis Precision Medicines to $40 From $41 After $200 Million Secondary Offering, Maintains Neutral Rating
Analysts' Top Healthcare Picks: Praxis Precision Medicines (PRAX), GlycoMimetics (GLYC)
Jefferies Adjusts Praxis Precision Medicines' Price Target to $128 From $75, Keeps Buy Rating
Praxis Precision Medicine Analyst Ratings
Analysis
Price Target
No Data
